BTG plc (BTG) Earns “Neutral” Rating from J P Morgan Chase & Co
BTG plc (LON:BTG)‘s stock had its “neutral” rating reiterated by stock analysts at J P Morgan Chase & Co in a research report issued on Monday.
BTG has been the topic of a number of other research reports. Stifel Nicolaus reissued a “buy” rating and issued a GBX 800 ($10.33) price objective on shares of BTG plc in a research report on Wednesday, August 30th. Numis Securities Ltd reissued a “buy” rating and issued a GBX 900 ($11.62) price objective on shares of BTG plc in a research report on Wednesday, August 9th. Panmure Gordon cut their price objective on shares of BTG plc from GBX 809 ($10.45) to GBX 793 ($10.24) and set a “buy” rating on the stock in a research report on Monday, May 22nd. Finally, Shore Capital reissued a “not rated” rating on shares of BTG plc in a research report on Thursday, July 13th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. BTG plc currently has a consensus rating of “Buy” and an average price target of GBX 774.78 ($10.01).
BTG plc (BTG) opened at 660.50 on Monday. The stock’s 50 day moving average is GBX 671.58 and its 200-day moving average is GBX 652.86. BTG plc has a 12-month low of GBX 528.36 and a 12-month high of GBX 738.50. The company’s market cap is GBX 2.54 billion.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.